Scientific publications

April 2019
Phase 1b/2 Study of CD40 Agonistic Antibody APX005M in Combination with Nivolumab (Nivo) in Subjects with Metastatic Melanoma (M) and Subjects with Non-Small Cell Lung Cancer (NSCLC)
AACR Poster
March 2019
A Phase 1b Study of CD40 Agonistic Monoclonal Antibody APX005M Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Patients
AACR Presentation
January 2019
A Phase 1b Study of CD40 Agonistic Monoclonal Antibody APX005M Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Ductal Pancreatic Adenocarcinoma (PDAC) Patients
ASCO GI Abstract
June 2018
Phase I/II Dose Escalation and Expansion Study of Image Guided Intratumoral APX005M in Combination with Systemic Pembrolizumab in Treatment Naïve Metastatic Melanoma Patients
ASCO Poster
November 2017
A Phase Ib/II Study of CD40 Agonistic Monoclonal Antibody (APX005M) Together with Gemcitabine and nab-Paclitaxel with or without Nivolumabin Untreated Metastatic Pancreatic Adenocarcinoma Patients
SITC Poster
November 2017
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma
SITC Poster
November 2017
A Pilot Study to Evaluate The Clinical and Immunological Effects of Incorporating a CD40-Agonistic Antibody into the Multimodality Treatment of Resectable Esophageal and GE Junction Cancersrcoma
SITC Poster
November 2017
Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors
SITC Poster
November 2017
First in Human Study with the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors
SITC Presentation